Ignite Creation Date:
2025-12-25 @ 3:46 AM
Ignite Modification Date:
2025-12-26 @ 2:32 AM
Study NCT ID:
NCT05984602
Status:
RECRUITING
Last Update Posted:
2025-04-15
First Post:
2023-08-02
Is NOT Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
A Phase IB Study to Determine the Safety and Tolerability of Canakinumab and Tislelizumab in Combination With Nab-Paclitaxel and Gemcitabine in the Neo-adjuvant Treatment of Patients With Pancreatic Cancer
Sponsor:
NYU Langone Health
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2023-07-14
Start Date Type:
ACTUAL
Primary Completion Date:
2025-08-01
Primary Completion Date Type:
ESTIMATED
Completion Date:
2026-01-01
Completion Date Type:
ESTIMATED
First Submit Date:
2023-08-02
First Submit QC Date:
None
Study First Post Date:
2023-08-09
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-04-11
Last Update Post Date:
2025-04-15
Last Update Post Date Type:
ACTUAL